Anokion, a Lausanne, Switzerland-based clinical-stage biotechnology company, raised $35M in Equity funding.
The round was led by Pfizer Breakthrough Growth Initiative. In conjunction with the funding, Michael Vincent, M.D., Ph.D., senior vice president and chief scientific officer, Inflammation & Immunology, Pfizer, joined the company’s scientific advisory board, which will be announced later this year, and Allison Kean, M.D., executive director, Worldwide Business Development, Pfizer joined Anokion’s board of directors as an observer.
Separately, Anokion and Pfizer have entered into an agreement to leverage Pfizer’s development expertise and capabilities in support of the continued clinical development of KAN-101, Anokion’s lead candidate for the treatment of individuals with celiac disease.
The company intends to use a portion of the proceeds to fund its Phase 2 clinical program of KAN-101 for the treatment of individuals with celiac disease, a serious autoimmune disorder triggered by ingestion of gluten, for which there are no approved therapeutic treatments available.
Led by Deborah Geraghty, Ph.D., CEO, Anokion SA is a clinical-stage biotechnology company focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes. Its approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease.
The company has an office in Cambridge, MA.
FinSMEs
18/10/2022